Tempus AI CEO Eric Lefkofsky Sells $7.76M in Company Stock

Tempus AI Inc. CEO and founder Eric Lefkofsky sold $7.76 million worth of company shares, according to an SEC Form 4 filed on May 29, 2026. The transaction involved the sale of 165,000 shares at an average price of $47.03, executed on May 28. This sale precedes the expiration of the post-initial public offering (IPO) lockup period, a critical liquidity window for company insiders and early investors.

Context — [why this matters now]

The sale coincides with a pivotal transition for Tempus AI. The company, which debuted on the Nasdaq in June 2025, is approaching the end of its 180-day post-IPO lockup period that restricted insider sales. Historically, shares of newly public companies face significant selling pressure as these lockups expire, increasing the available float. A comparable event occurred on January 15, 2026, when Guardant Health CEO Helmy Eltoukhy sold $5.2 million in shares just weeks before that company's lockup expiry.

The current macro backdrop features elevated equity volatility, with the VIX index trading near 18.50. Interest rates remain high, with the 10-year Treasury yield at 4.25%, pressuring growth-oriented stocks like Tempus AI. The IPO market for healthcare technology firms has been selective, with few new listings in 2026.

The immediate trigger for the transaction was likely the impending lockup expiry. This creates a known liquidity event for early backers and company executives. Lefkofsky, a serial entrepreneur with a history of founding and taking companies public, is known for strategic portfolio management. His timing signals a planned rebalancing ahead of a period of anticipated volatility.

Data — [what the numbers show]

The executed sale comprised 165,000 shares. The transaction price of $47.03 represents a 22% discount from the stock's 52-week high of $60.50, achieved in February 2026. Following the sale, Lefkofsky retains direct ownership of approximately 22.5 million shares, maintaining a controlling stake of roughly 28% of total outstanding shares.

A key metric is the percentage of his total position sold. The $7.76 million sale represents less than 0.5% of his remaining holdings post-transaction. This is a critical distinction from a full-scale liquidation. For context, the company's total market capitalization stands at approximately $3.8 billion.

The stock performance relative to peers is mixed. Since its IPO, Tempus AI shares are down 12%, while the iShares Biotechnology ETF (IBB) is up 3% year-to-date. In the week preceding the filing, daily trading volume averaged 1.2 million shares. The $7.76 million sale volume equates to roughly 150% of a single day's average volume, indicating the transaction was likely executed via a block trade to minimize market impact.

Metric	Value
Shares Sold	165,000
Average Price	$47.03
Total Sale Value	$7.76M
Remaining CEO Holdings	~22.5M shares

Analysis — [what it means for markets / sectors / tickers]

The direct market effect is a temporary increase in selling pressure on Tempus AI shares, potentially widening the bid-ask spread around the lockup expiry date. The transaction provides a tangible price discovery point for large blocks of stock, setting a temporary ceiling near $47. A secondary effect is increased scrutiny on other pre-lockup healthcare tech names like Precision Biosciences (DTIL) and Recursion Pharmaceuticals (RXRX), which may see relative outperformance if investors rotate out of Tempus.

A counter-argument is that the sale is financially insignificant relative to Lefkofsky's total holdings and likely part of a routine financial planning strategy. Insiders sell stock for numerous non-predictive reasons, including tax obligations, estate planning, and portfolio diversification. Historical data shows no consistent correlation between single, small-percentage insider sales and subsequent long-term stock underperformance.

Positioning data from options markets shows an increase in put option volume for Tempus AI, with a concentration at the $45 strike price expiring in June. This suggests some institutional investors are hedging against further downside around the lockup event. Flow is moving towards more established, profitable diagnostics firms like Quest Diagnostics (DGX) and Labcorp (LH), which offer stability amid the uncertainty.

Outlook — [what to watch next]

The primary catalyst is the official lockup expiry date, expected around June 20, 2026. Market attention will focus on Form 4 filings from other major pre-IPO investors and board members to gauge if Lefkofsky's sale is an outlier or the start of a trend. The next Tempus AI earnings report is scheduled for August 5, 2026, which will provide an update on revenue growth and burn rate.

Key technical levels for the stock include immediate support at $45.50, its 200-day moving average. A break below this level could target the $42 support zone established after its IPO. Resistance sits at the $50 psychological level and the 50-day moving average near $51.20. The 10-year Treasury yield remaining above 4.20% continues to act as a headwind for high-multiple growth stocks.

Investor focus will shift to whether the company can demonstrate a clear path to profitability. Commentary on upcoming product launches in its AI-driven clinical trial matching platform will be critical. Any guidance revision during the August earnings call will significantly outweigh the near-term noise from the lockup expiry.

Frequently Asked Questions

Is Eric Lefkofsky leaving Tempus AI?

No, the filing indicates a sale of shares only, not a departure from his role. Lefkofsky remains CEO, Chairman, and the company's largest individual shareholder with approximately 28% of outstanding shares. His remaining stake of over 22 million shares is heavily aligned with the company's long-term performance. Executive departures are disclosed in different SEC filings, such as Form 8-K.

How does this sale compare to other recent biotech insider sales?

The sale is moderate in size relative to the sector. In April 2026, the CEO of CRISPR Therapeutics sold $15 million in stock, representing a larger percentage of his holdings. The Tempus sale is more aligned with planned, partial liquidity events common before lockup expiries rather than distress selling. It lacks the concentrated, high-volume selling sometimes seen when venture capital firms fully exit a position post-IPO.

What is a post-IPO lockup period and why does it exist?

A lockup period is a contractual restriction, typically 90 to 180 days, preventing company insiders and early investors from selling shares immediately after an IPO. It exists to prevent a sudden flood of new shares onto the market, which could destabilize the stock price and undermine investor confidence in the offering. The expiry date is publicly known and often leads to increased trading volatility in the surrounding weeks.